Dizal (Jiangsu) Pharmaceutical Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Mar'24

Net Sales

231.30

195.36

159.64

21.45

134.90

122.23

81.32

Other Operating Income

0.00

Total Operating income

231.30

195.36

159.64

21.45

134.90

122.23

81.32

Raw Material Cost

9.70

27.15

25.67

20.77

22.08

22.07

21.41

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

6.44

8.66

8.50

7.31

5.97

5.22

4.25

Selling and Distribution Expenses

202.33

178.08

151.92

154.83

158.52

145.22

123.52

Other Expenses

22.95

17.50

18.76

13.41

16.45

15.71

18.48

Total Expenditure (Excl Depreciation)

448.00

388.92

373.67

317.04

351.03

329.59

334.00

Operating Profit (PBDIT) excl Other Income

-216.70000000000002

-193.6

-214

-295.59999999999997

-216.1

-207.39999999999998

-252.7

Other Income

12.91

10.16

25.56

9.86

1.65

1.83

29.11

Operating Profit (PBDIT)

-204.81

-165.61

-170.26

-267.06

-195.78

-187.02

-204.46

Interest

6.44

8.66

8.50

7.31

5.97

5.22

4.25

Exceptional Items

7.34

7.61

3.61

3.52

3.56

3.54

3.83

Gross Profit (PBDT)

221.60

168.21

133.97

0.68

112.82

100.16

59.91

Depreciation

0.00

18.60

19.15

19.36

Profit Before Tax

-203.91

-185.25

-193.74

-290.01

-217.35

-208.06

-224.23

Tax

0.00

0.05

0.00

Provisions and contingencies

0.00

Profit After Tax

-202.59

-184.85

-192.51

-287.50

-213.71

-120.52

-224.23

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-202.59

-184.85

-192.51

-287.50

-213.71

-120.52

-224.23

Share in Profit of Associates

0.00

Minority Interest

-1.32

-0.45

-1.23

-2.51

-3.64

-87.55

0.00

Other related items

0.00

Consolidated Net Profit

-203.91

-185.30

-193.74

-290.01

-217.35

-208.06

-224.23

Equity Capital

0.00

Face Value

1.0

Reserves

1,440.44

1,624.16

18.46

193.76

428.43

609.06

696.59

Earnings per share (EPS)

-0.44

-0.4

-0.46

-0.69

-0.51

-0.29

-0.54

Diluted Earnings per share

-0.44

-0.4

-0.46

-0.69

-0.51

-0.29

-0.54

Operating Profit Margin (Excl OI)

-94.13%

-99.49%

-134.31%

-1380.35%

-160.55%

-170.34%

-311.03%

Gross Profit Margin

-88.16%

-85.31%

-109.71%

-1262.74%

-146.92%

-154.38%

-251.95%

PAT Margin

-87.59%

-94.62%

-120.59%

-1340.33%

-158.42%

-98.6%

-275.75%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Sep 2025 is 71.46% vs 236.41% in Sep 2024

Consolidate Net Profit

YoY Growth in quarter ended Sep 2025 is 6.17% vs 30.95% in Sep 2024

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Sep 2025 is -10.28% vs 33.96% in Sep 2024

Interest

YoY Growth in quarter ended Sep 2025 is 6.67% vs 160.87% in Sep 2024

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024

Compare Quarterly Results Of Dizal (Jiangsu) Pharmaceutical Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

231.30

Other Operating Income

0.00

Total Operating income

231.30

Raw Material Cost

9.70

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

6.44

Selling and Distribution Expenses

202.33

Other Expenses

22.95

0.00

22.95

Total Expenditure (Excl Depreciation)

448.00

Operating Profit (PBDIT) excl Other Income

-216.70

0.00

-216.70

Other Income

12.91

Operating Profit (PBDIT)

-204.81

Interest

6.44

Exceptional Items

7.34

Gross Profit (PBDT)

221.60

Depreciation

0.00

Profit Before Tax

-203.91

Tax

0.00

Provisions and contingencies

0.00

Profit After Tax

-202.59

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

-202.59

Share in Profit of Associates

0.00

Minority Interest

-1.32

Other related items

0.00

Consolidated Net Profit

-203.91

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

1,440.44

Earnings per share (EPS)

-0.44

Diluted Earnings per share

-0.44

Operating Profit Margin (Excl OI)

-94.13%

0.00

-94.13%

Gross Profit Margin

-88.16%

0.00

-88.16%

PAT Margin

-87.59%

0.00

-87.59%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 23.13 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is 18.37% vs 22.43% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 71.46% vs 236.41% in Sep 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit -20.39 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -10.04% vs 4.34% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 6.17% vs 30.95% in Sep 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) -21.77 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -23.83% vs 10.21% in Jun 2025

YoY Growth in quarter ended Sep 2025 is -10.28% vs 33.96% in Sep 2024

Quarterly - Interest

Interest 0.64 Million

in Sep 2025

Figures in Million

QoQ Growth in quarter ended Sep 2025 is -26.44% vs 2.35% in Jun 2025

YoY Growth in quarter ended Sep 2025 is 6.67% vs 160.87% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) -94.13%

in Sep 2025

Figures in %

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024